A Study of TQ-B3525 on Tolerance and Pharmacokinetics

C

CTTQ

Status and phase

Enrolling
Phase 1

Conditions

Relapsed or Refractory Lymphoma or Advanced Cancer

Treatments

Drug: TQ-B3525

Study type

Interventional

Funder types

Industry

Identifiers

NCT03510767
TQ-B3525-I-01

Details and patient eligibility

About

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
  • ECOG PS≤1
  • Adequate blood cell counts, kidney function and liver function
  • Patients should participate in the study voluntarily and sign informed consent

Exclusion criteria

  • Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
  • Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
  • Hepatitis B virus patients with active replication (DNA> 500 cps / mL), hepatitis C

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 1 patient group

TQ-B3525
Experimental group
Treatment:
Drug: TQ-B3525

Trial contacts and locations

1

Loading...

Central trial contact

Huaqing Wang, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems